New drug combo shows promise for Hard-to-Treat breast cancer

NCT ID NCT03179904

First seen Jun 26, 2026 · Last updated Jul 02, 2026 · Updated 3 times

Summary

This phase 2 trial tests a new drug called TVB-2640 (denifanstat) combined with trastuzumab and either chemotherapy (paclitaxel) or hormone therapy in 17 people with HER2+ metastatic breast cancer that no longer responds to trastuzumab. TVB-2640 blocks an enzyme cancer cells need to grow, while trastuzumab targets HER2 receptors. The goal is to see if this combination can shrink tumors and control the disease.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Denifanstat (TVB-2640), a FASN inhibitor, combined with trastuzumab and either paclitaxel or endocrine therapy
What this could lead to
If successful, this could offer a new treatment option for people with HER2+ metastatic breast cancer whose cancer has stopped responding to standard trastuzumab-based therapy.
What could go wrong
This is a small, early-phase trial with only 17 participants, so results may not apply to everyone. The combination may cause side effects or fail to shrink tumors in many patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED BREAST CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Mayo Clinic in Arizona

    Scottsdale, Arizona, 85259, United States

  • Mayo Clinic in Florida

    Jacksonville, Florida, 32224-9980, United States

  • Mayo Clinic in Rochester

    Rochester, Minnesota, 55905, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.